Precipio (PRPO) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Precipio (PRPO) overview

Precipio (PRPO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 24.0m and operating profit of USD -1.2m; the year-end share price was 22.98 USD and market capitalisation was USD 40.9m. Precipio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Precipio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 14.6mFY 2025
Share price22.98 USDFY 2025 year end
RevenueUSD 24.0mFY 2025
Operating profitUSD -1.2mFY 2025
Net earningsUSD -0.4mFY 2025
Market capitalisationUSD 40.9mFY 2025 year end

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics, particularly hematologic malignancies. It provides specialized pathology testing services to physicians, hospitals, and laboratories, including molecular diagnostics, cytogenetics, and other laboratory analyses using patient samples. The company also develops and commercializes proprietary diagnostic assays and kits for clinical laboratories, drawing on its laboratory operations to support product evaluation and validation.

Generate the Precipio report

Precipio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Precipio and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Precipio

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.